Holen Sie sich die Stockscreener-App
25.17
6.98%
-1.89
Handel nachbörslich:
25.11
-0.06
-0.24%
Schlusskurs vom Vortag:
$27.06
Offen:
$26.56
24-Stunden-Volumen:
1.38M
Relative Volume:
1.62
Marktkapitalisierung:
$2.50B
Einnahmen:
$322.71M
Nettoeinkommen (Verlust:
$-298.33M
KGV:
-6.139
EPS:
-4.1
Netto-Cashflow:
$-218.98M
1W Leistung:
-19.04%
1M Leistung:
-8.44%
6M Leistung:
+29.74%
1J Leistung:
-8.71%
1-Tages-Spanne:
$24.85
$26.91
1-Wochen-Bereich:
$24.85
$32.15
52-Wochen-Spanne:
$13.48
$36.60
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Firmenname
Zai Lab Limited Adr
Sektor
Branche
Telefon
862161632588
Adresse
4560 JINKE ROAD, SHANGHAI
Vergleichen Sie ZLAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ZLAB | 25.17 | 2.50B | 322.71M | -298.33M | -218.98M | -4.10 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-21 | Eingeleitet | Macquarie | Outperform |
| 2021-10-12 | Eingeleitet | Bernstein | Mkt Perform |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-04-15 | Eingeleitet | Guggenheim | Buy |
| 2019-07-12 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
| 2019-01-29 | Eingeleitet | Credit Suisse | Outperform |
| 2018-11-21 | Eingeleitet | Jefferies | Buy |
| 2018-06-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Eingeleitet | JP Morgan | Neutral |
| 2017-10-16 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Zai Lab Limited Adr Aktie (ZLAB) Neueste Nachrichten
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares - BioSpace
ZLABZai Lab Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Zai Lab Raises $230M in Oversubscribed Public Offering of American Depositary Shares | ZLAB Stock News - StockTitan
FY2024 EPS Estimates for Zai Lab Increased by Analyst - Defense World
Zai Lab (NASDAQ:ZLAB) Sees Strong Trading Volume – Here’s What Happened - Defense World
Digital Brands Group Inc (DBGI): Is It Worth A Small Bite At $0.10? - Stocks Register
Thermo Fisher Scientific Inc’s (TMO) Stock Is Harder To Predict Than You Think - Stocks Register
Selling Your MicroAlgo Inc (NASDAQ: MLGO) Stock? Here’s What You Need To Know - Stocks Register
Danaher Corp (DHR): An Important Analyst Insights - Stocks Register
Centerpoint Energy Inc (NYSE: CNP): Blank Check On Growth? - Stocks Register
Do Unitedhealth Group Inc (NYSE: UNH) Provide Stability And Growth? - Stocks Register
Major Improvements In VF Corp (VFC) Stock Need To Be Considered - Stocks Register
A Stock Analysis Of Fortive Corp’s (FTV) - Stocks Register
Dollar Tree Inc’s (DLTR) Stock Is Harder To Predict Than You Think - Stocks Register
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
Leerink Partnrs Increases Earnings Estimates for Zai Lab - Defense World
Zai Lab Announces $200M Public Offering at $25.50 per ADS | ZLAB Stock News - StockTitan
Zai Lab Announces Pricing of Public Offering of American Depositary Shares - Business Wire
Zai Lab Launches $200M ADS Offering with Goldman Sachs, Jefferies as Lead Managers | ZLAB Stock News - StockTitan
Zai Lab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Zai Lab Ltd (ZLAB) Reports Q3 2024 Earnings: EPS Loss of $0.04, Revenue at $101.8 Million, Slightly Misses Estimates - GuruFocus.com
abrdn Life Sciences Investors declares $0.50 dividend - MSN
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates - Business Wire
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for - GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Business Wire
Zai Lab (ZLAB) Scheduled to Post Quarterly Earnings on Tuesday - Defense World
Zai Lab Limited (NASDAQ:ZLAB) Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
JP Morgan analysts reiterates an Overweight rating for Roku Inc (ROKU) - Knox Daily
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China - Business Wire
DaVita Inc. (NYSE:DVA) Q3 2024 Earnings Call Transcript - MSN
Zai Lab (NASDAQ:ZLAB) Stock Price Down 3.7% – Here’s What Happened - Defense World
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? - MSN
Biopharma operator Zai Lab surges to 16-month high on lung cancer drug trial results - Mugglehead
Trial highlights potential next-gen biologic for lung cancer - Marketscreener.com
Zai Lab (NASDAQ:ZLAB) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Down 3.7%What's Next? - MarketBeat
Hennion & Walsh Asset Management Inc. Boosts Stake in Zai Lab Limited (NASDAQ:ZLAB) - MarketBeat
Zai Lab stock soars to 52-week high, touches $32.5 - Investing.com India
Citi raises Zai Lab target on promising trial results - Investing.com
This Biotech Leader Just Hit A 16-Month High On An 'Impressive' Test - Investor's Business Daily
Zai Lab (NASDAQ:ZLAB) Hits New 12-Month HighHere's What Happened - MarketBeat
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer - BioSpace
Zai Lab Announces Participation in November and December Investor Conferences - BioSpace
JPMorgan Chase & Co. Raises Zai Lab (NASDAQ:ZLAB) Price Target to $44.00 - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Up 6.5% – Still a Buy? - Defense World
Zai Lab (NASDAQ:ZLAB) Stock Price Up 6.5%Here's What Happened - MarketBeat
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 - Business Wire
Zai Lab (NASDAQ:ZLAB) Shares Gap UpShould You Buy? - MarketBeat
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 - BioSpace
Dimensional Fund Advisors LP Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Finanzdaten der Zai Lab Limited Adr-Aktie (ZLAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):